Wednesday, 28 Jun 2017

You are here

RheumNow Week in Review – 14 October 2015

Dr Jack Cush reviews highlights from the news and journal articles appearing this week on RheumNow.com:

  1. Prevalence of noninfectious uveitis in USA: Nearly 300,000 adults and 22,000 children in 2015 (based on claims data). http://buff.ly/2e7ew4y
  2. Global biosimilars sales = 3.5 billion in 2015; poised to reach $15.6 billion by 2022. https://t.co/TATv2rgYTM
  3. Patients with VERY high levels of CRP & nonspecific findings should raise suspicion for other non-rheumatic diagnoses (infection, malignancy). https://t.co/xbCTGXPd5L
  4. Medicare study shows no increased risk of breast cancer in RA or IBD women taking MTX, 6MP or TNF inhibitors! https://t.co/lHyUbyjNCQ
  5. Norwegian HUNT study shows no increased risk of fracture among 2804 self reported psoriasis patients. https://t.co/PHNMUac27A
  6. High ESR/CRP in a Rheumatology Hospital: Rheumatic diseases were most common (52%); lead by PMR (38%), seronegative RA, infection (25%), neoplasia (9%). https://t.co/9mkJhQMXwZd
  7. Diabetes has frequent articular and periarticular findings: including OA knee (most common at 49%), carpal tunnel syndrome (29%), frozen shoulder (23%), cheiroarthropathy (16%). https://t.co/pGRNI6wQTQ
  8. Metanalysis: ankle replacement (TAA) vs arthrodeisis w/ similar outcomes but more reoperations, complications w/ TAA. https://t.co/dGbZLl28mi
  9. Phase II ACCLAIM small trial fails to show significant benefit/safety of Abatacept in multiple sclerosis (42 pts). https://t.co/GeU5XnhePt
  10. Endocannabinoid, Resunab (JBT-101), in a clinical trial for scleroderma. It decreases TGF-B & collagen. https://t.co/Iu8OLPm5BC
  11. Mayo study of incident Sarcoidosis shows 3 fold higher risk of venous thrombosis & 4 fold risk of pulm embolism. https://t.co/C4gZc951aJ
  12. My Take on New Ocular Screening Guidelines for Plaquenil 
  13. 1/3 of First Degree Relatives to AS patients are at Risk of Spondyloarthritis
  14. New Criteria for the Cryopyrinopathies (CAPS)
  15. Long-Term Outcomes of Aromatase Inhibitor Arthralgias
Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

ACR Says Senate Healthcare Bill Falls Short of Protecting Americans with Rheumatic Disease

Dr. Sharad Lakhanpal, President of the American College of Rheumatology has responded to the Senate's proposed changes to healthcare coverage in the USA.

Highlights from EULAR 2017 - From RheumReports.com

Dr. Janet Pope reviews her favorite and least favorite presentations and abstracts from EULAR 2017. 

The RheumNow Week in Review – How to ACR/EULAR 23 June 2017

Dr. Jack Cush reviews his approach to attending and getting the most out of ACR or EULAR Congress meetings.

EULAR 2017 – Day 4 Highlights

Saturday was a day of big posters and special seminars at EULAR in Madrid.  In the morning, I passed on an interesting session on nailfold capillaroscopy led by Dr. M Cutolo and went to a JIA outcomes session. I reported on this in a video from day 4 (Saturday) called “Long-Term Comorbidities in JIA” – you can find it here.

Responder Criteria for Nonpharmalogical Treatment of Fibromyalgia.

Because of the subjective nature of fibromyalgia symptoms, tools for monitoring of disease activity and/or treatment assessment tools to evaluate effectiveness of nonpharmacological modalities are difficult to develop.